Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.2800
- TODAY'S CHANGE (%)0.0200 (0.4695%)
- Bid / Lots4.2100/ 57
- Ask / Lots4.3900/ 59
- Open / Previous Close4.2900 / 4.2600
- Day Range
- 52 Week Range
- Volume442,389
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 6527 | 4.28 |
| 09:33 ET | 1208 | 4.3 |
| 09:35 ET | 14242 | 4.35 |
| 09:37 ET | 8766 | 4.365 |
| 09:42 ET | 600 | 4.375 |
| 09:44 ET | 13309 | 4.38 |
| 09:46 ET | 4239 | 4.385 |
| 09:48 ET | 8394 | 4.3703 |
| 09:50 ET | 2600 | 4.365 |
| 09:51 ET | 1750 | 4.365 |
| 09:53 ET | 200 | 4.365 |
| 09:55 ET | 7666 | 4.345 |
| 09:57 ET | 1600 | 4.34 |
| 10:00 ET | 500 | 4.34 |
| 10:02 ET | 5950 | 4.315 |
| 10:04 ET | 400 | 4.325 |
| 10:06 ET | 100 | 4.33 |
| 10:08 ET | 5038 | 4.32 |
| 10:09 ET | 500 | 4.325 |
| 10:11 ET | 2030 | 4.345 |
| 10:13 ET | 788 | 4.335 |
| 10:15 ET | 700 | 4.34 |
| 10:18 ET | 1342 | 4.345 |
| 10:22 ET | 300 | 4.345 |
| 10:24 ET | 7732 | 4.355 |
| 10:26 ET | 200 | 4.355 |
| 10:27 ET | 2532 | 4.34 |
| 10:29 ET | 5679 | 4.345 |
| 10:31 ET | 1000 | 4.345 |
| 10:33 ET | 200 | 4.34 |
| 10:36 ET | 1459 | 4.335 |
| 10:38 ET | 9791 | 4.335 |
| 10:40 ET | 620 | 4.33 |
| 10:42 ET | 2003 | 4.335 |
| 10:44 ET | 2426 | 4.35 |
| 10:45 ET | 3865 | 4.35 |
| 10:47 ET | 1775 | 4.345 |
| 10:49 ET | 100 | 4.345 |
| 10:51 ET | 5246 | 4.325 |
| 10:54 ET | 100 | 4.325 |
| 10:56 ET | 100 | 4.32 |
| 10:58 ET | 800 | 4.325 |
| 11:00 ET | 3526 | 4.325 |
| 11:02 ET | 100 | 4.325 |
| 11:03 ET | 4482 | 4.33 |
| 11:05 ET | 200 | 4.335 |
| 11:07 ET | 1260 | 4.345 |
| 11:09 ET | 6419 | 4.345 |
| 11:12 ET | 1150 | 4.32 |
| 11:14 ET | 800 | 4.315 |
| 11:16 ET | 3444 | 4.335 |
| 11:18 ET | 300 | 4.335 |
| 11:20 ET | 800 | 4.33 |
| 11:23 ET | 400 | 4.335 |
| 11:25 ET | 1859 | 4.335 |
| 11:27 ET | 1100 | 4.345 |
| 11:30 ET | 10025 | 4.33 |
| 11:32 ET | 100 | 4.335 |
| 11:34 ET | 1279 | 4.32 |
| 11:36 ET | 677 | 4.325 |
| 11:38 ET | 1155 | 4.315 |
| 11:39 ET | 2712 | 4.315 |
| 11:41 ET | 500 | 4.315 |
| 11:43 ET | 400 | 4.315 |
| 11:45 ET | 700 | 4.315 |
| 11:48 ET | 826 | 4.315 |
| 11:50 ET | 10598 | 4.31 |
| 11:52 ET | 200 | 4.305 |
| 11:54 ET | 1288 | 4.295 |
| 11:56 ET | 1104 | 4.285 |
| 11:57 ET | 12526 | 4.285 |
| 11:59 ET | 600 | 4.285 |
| 12:01 ET | 5553 | 4.31 |
| 12:03 ET | 1176 | 4.305 |
| 12:06 ET | 100 | 4.305 |
| 12:10 ET | 1200 | 4.3 |
| 12:14 ET | 1004 | 4.3 |
| 12:15 ET | 200 | 4.295 |
| 12:17 ET | 300 | 4.295 |
| 12:19 ET | 300 | 4.295 |
| 12:21 ET | 300 | 4.295 |
| 12:24 ET | 1072 | 4.295 |
| 12:26 ET | 400 | 4.295 |
| 12:30 ET | 700 | 4.29 |
| 12:32 ET | 12027 | 4.29 |
| 12:33 ET | 1278 | 4.28 |
| 12:35 ET | 952 | 4.295 |
| 12:39 ET | 100 | 4.295 |
| 12:42 ET | 400 | 4.295 |
| 12:44 ET | 816 | 4.295 |
| 12:46 ET | 3659 | 4.29 |
| 12:48 ET | 1951 | 4.285 |
| 12:50 ET | 600 | 4.29 |
| 12:51 ET | 1600 | 4.295 |
| 12:55 ET | 200 | 4.295 |
| 01:00 ET | 2626 | 4.295 |
| 01:04 ET | 1100 | 4.285 |
| 01:06 ET | 1393 | 4.2847 |
| 01:08 ET | 352 | 4.285 |
| 01:09 ET | 2504 | 4.285 |
| 01:11 ET | 100 | 4.285 |
| 01:13 ET | 1586 | 4.27 |
| 01:15 ET | 200 | 4.27 |
| 01:18 ET | 800 | 4.27 |
| 01:20 ET | 200 | 4.28 |
| 01:22 ET | 1302 | 4.27 |
| 01:24 ET | 400 | 4.275 |
| 01:26 ET | 683 | 4.265 |
| 01:27 ET | 1508 | 4.275 |
| 01:29 ET | 597 | 4.275 |
| 01:31 ET | 252 | 4.275 |
| 01:33 ET | 1000 | 4.285 |
| 01:36 ET | 200 | 4.295 |
| 01:38 ET | 200 | 4.2928 |
| 01:42 ET | 700 | 4.295 |
| 01:44 ET | 704 | 4.295 |
| 01:47 ET | 298 | 4.295 |
| 01:49 ET | 1700 | 4.3 |
| 01:51 ET | 600 | 4.305 |
| 01:54 ET | 200 | 4.305 |
| 01:56 ET | 126 | 4.305 |
| 01:58 ET | 367 | 4.31 |
| 02:02 ET | 226 | 4.305 |
| 02:05 ET | 2061 | 4.295 |
| 02:07 ET | 752 | 4.295 |
| 02:12 ET | 700 | 4.295 |
| 02:14 ET | 926 | 4.295 |
| 02:18 ET | 626 | 4.295 |
| 02:20 ET | 1178 | 4.295 |
| 02:21 ET | 962 | 4.295 |
| 02:23 ET | 1193 | 4.29 |
| 02:25 ET | 457 | 4.28 |
| 02:32 ET | 536 | 4.26 |
| 02:36 ET | 500 | 4.265 |
| 02:38 ET | 3404 | 4.275 |
| 02:43 ET | 352 | 4.275 |
| 02:48 ET | 600 | 4.275 |
| 02:50 ET | 474 | 4.275 |
| 02:52 ET | 1468 | 4.275 |
| 02:54 ET | 1177 | 4.275 |
| 02:56 ET | 21458 | 4.285 |
| 02:57 ET | 600 | 4.29 |
| 02:59 ET | 1344 | 4.305 |
| 03:01 ET | 300 | 4.3 |
| 03:03 ET | 5800 | 4.285 |
| 03:10 ET | 1934 | 4.285 |
| 03:12 ET | 300 | 4.29 |
| 03:14 ET | 200 | 4.285 |
| 03:17 ET | 300 | 4.29 |
| 03:19 ET | 400 | 4.285 |
| 03:21 ET | 300 | 4.285 |
| 03:24 ET | 149 | 4.285 |
| 03:28 ET | 400 | 4.285 |
| 03:30 ET | 300 | 4.285 |
| 03:32 ET | 500 | 4.285 |
| 03:33 ET | 300 | 4.285 |
| 03:35 ET | 200 | 4.285 |
| 03:37 ET | 100 | 4.28 |
| 03:39 ET | 400 | 4.285 |
| 03:42 ET | 1100 | 4.285 |
| 03:44 ET | 700 | 4.285 |
| 03:46 ET | 1159 | 4.29 |
| 03:48 ET | 5845 | 4.27 |
| 03:50 ET | 3331 | 4.265 |
| 03:51 ET | 3883 | 4.265 |
| 03:53 ET | 1300 | 4.26 |
| 03:55 ET | 5825 | 4.26 |
| 03:57 ET | 19295 | 4.27 |
| 04:00 ET | 19860 | 4.28 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 655.4M | -16.2x | --- |
AnaptysBio Inc | 648.4M | -3.7x | --- |
Korro Bio Inc | 654.6M | -2.4x | --- |
Alumis Inc | 653.9M | -3.2x | --- |
Savara Inc | 653.5M | -9.4x | --- |
Tectonic Therapeutic Inc | 647.7M | -2.5x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $655.4M |
|---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-0.26 |
Book Value | $0.36 |
P/E Ratio | -16.2x |
Price/Sales (TTM) | 540.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,918.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
